South Korea · Delayed Price · Currency is KRW Next Biomedical Statistics
Total Valuation
Next Biomedical has a market cap or net worth of KRW 321.99 billion. The enterprise value is 295.81 billion.
| Market Cap | 321.99B |
| Enterprise Value | 295.81B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Next Biomedical has 8.28 million shares outstanding. The number of shares has increased by 6.44% in one year.
| Current Share Class | 8.28M |
| Shares Outstanding | 8.28M |
| Shares Change (YoY) | +6.44% |
| Shares Change (QoQ) | -0.91% |
| Owned by Insiders (%) | 31.24% |
| Owned by Institutions (%) | 5.67% |
| Float | 5.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.14 |
| PB Ratio | 6.58 |
| P/TBV Ratio | 6.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 898.90 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.11, with a Debt / Equity ratio of 0.15.
| Current Ratio | 5.11 |
| Quick Ratio | 4.59 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.74 |
| Interest Coverage | -3.94 |
Financial Efficiency
Return on equity (ROE) is -0.08% and return on invested capital (ROIC) is -1.38%.
| Return on Equity (ROE) | -0.08% |
| Return on Assets (ROA) | -1.31% |
| Return on Invested Capital (ROIC) | -1.38% |
| Return on Capital Employed (ROCE) | -2.40% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.85 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.51% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -6.51% |
| 50-Day Moving Average | 57,665.00 |
| 200-Day Moving Average | 69,206.75 |
| Relative Strength Index (RSI) | 36.26 |
| Average Volume (20 Days) | 86,115 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Next Biomedical had revenue of KRW 16.82 billion and -36.35 million in losses. Loss per share was -4.47.
| Revenue | 16.82B |
| Gross Profit | 11.79B |
| Operating Income | -1.24B |
| Pretax Income | -36.35M |
| Net Income | -36.35M |
| EBITDA | -711.61M |
| EBIT | -1.24B |
| Loss Per Share | -4.47 |
Balance Sheet
The company has 33.60 billion in cash and 7.43 billion in debt, with a net cash position of 26.18 billion or 3,162.65 per share.
| Cash & Cash Equivalents | 33.60B |
| Total Debt | 7.43B |
| Net Cash | 26.18B |
| Net Cash Per Share | 3,162.65 |
| Equity (Book Value) | 48.94B |
| Book Value Per Share | 6,036.01 |
| Working Capital | 32.91B |
Cash Flow
In the last 12 months, operating cash flow was 358.20 million and capital expenditures -3.07 billion, giving a free cash flow of -2.71 billion.
| Operating Cash Flow | 358.20M |
| Capital Expenditures | -3.07B |
| Depreciation & Amortization | 531.38M |
| Net Borrowing | -3.47B |
| Free Cash Flow | -2.71B |
| FCF Per Share | -327.78 |
Margins
Gross margin is 70.10%, with operating and profit margins of -7.39% and -0.22%.
| Gross Margin | 70.10% |
| Operating Margin | -7.39% |
| Pretax Margin | -0.22% |
| Profit Margin | -0.22% |
| EBITDA Margin | -4.23% |
| EBIT Margin | -7.39% |
| FCF Margin | n/a |
Dividends & Yields
Next Biomedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.44% |
| Shareholder Yield | -6.44% |
| Earnings Yield | -0.01% |
| FCF Yield | -0.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Next Biomedical is 97,666.67, which is 151.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 97,666.67 |
| Price Target Difference | 151.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 58.01% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Next Biomedical has an Altman Z-Score of 27.38 and a Piotroski F-Score of 5.
| Altman Z-Score | 27.38 |
| Piotroski F-Score | 5 |